Clinical Trial Update: Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating sublingual microdoses of 5-MeO-DMT for depression and anxiety has completed, reporting safety and tolerability with signals of effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Major Depressive Disorder

Drugs mentioned

• 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine)

Snippet

Sponsor: Biomind Labs Inc. | Conditions: Healthy Volunteers | Phase 1, Phase 2 | Status: COMPLETED